ArticleDiabetes, metabolic syndrome and obesity : targets and therapy2025
Psoas Muscle Index, Systemic Inflammation, and Liver Fibrosis in MAFLD: A Case-Control Study.
Article in Diabetes, metabolic syndrome and obesity : targets and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Investigating psoas muscle index (PMI) as a potential biomarker for metabolic dysfunction-associated fatty liver disease (MAFLD) and hepatic fibrosis through a case-control study. Methods: This case-control study enrolled 80 MAFLD patients and 80 healthy controls from our hospital (2023-2024). Abdominal CT-derived PMI, inflammatory markers, and FIB-4 scores were assessed. ROC and logistic regression analyses evaluated PMI's diagnostic potential for MAFLD and associated fibrosis. Results: A total of 160 patients met the inclusion criteria. Compared with the non-MAFLD group, the PMI and systemic inflammatory indicators in the MAFLD group were higher. In MAFLD patients, PMI was significantly correlated with systemic inflammation indicators, including the platelet-to-lymphocyte ratio (PLR), neutrophil-to-lymphocyte ratio (NLR), and systemic immune-inflammation index (SII) (P<0.001, P=0.038, and P<0.001, respectively). ROC curve analysis showed that the areas under the ROC curve (AUC) of PMI and other systemic inflammatory indicators (PLR, NLR, LMR, SII) for diagnosing MAFLD were 0.615, 0.526, 0.956, 0.803, and 0.674, respectively. The AUC of PMI combined with LMR, NLR, and LMR plus NLR for diagnosing MAFLD were 0.547, 0.585, and 0.572, respectively. FIB-4 was linearly correlated with PMI and systemic inflammatory indicators (PLR, NLR, SII) (r=-0.208, P=0.008; r=-0.211, P=0.007; r=0.327, P<0.001; r=0.164, P=0.039). The combination of PMI and systemic inflammatory indicators (PLR, NLR, SII) demonstrated a good diagnostic ability for liver fibrosis in MAFLD (AUC=0.602, P=0.003). Conclusion: PMI significantly correlates with systemic inflammation and hepatic fibrosis in MAFLD patients, serving as a diagnostic biomarker. Combined with inflammatory markers, it improves non-invasive screening efficacy for MAFLD/fibrosis. This study pioneers incorporating muscle metabolism into MAFLD diagnosis, with potential for primary care translation. Dynamic PMI monitoring may assess "muscle-liver axis" targeted therapies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.